Medvax

MedVax (Beijing) Biotechnology is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of personalized cancer immunotherapies. The company utilizes a proprietary neoantigen prediction and design platform to create tailored therapeutic vaccines for patients with various solid tumors. Its core technology involves identifying unique tumor mutations and developing peptide-based vaccines designed to stimulate a targeted immune response. MedVax is currently advancing its lead personalized vaccine candidates through Phase 1 and Phase 2 clinical trials, aiming to provide precision medicine solutions for highly heterogeneous cancers. The company has established significant collaborations with clinical centers to validate its platform and accelerate its pipeline development.